Evaluation of Serum Glial Cell Line-derived Neurotrophic Factor in Bangladeshi Major Depressive Disorder Patients

Background Major depressive disorder (MDD) is a global health burden in the 21(st) century because of its high rate of prevalence linked with disability, morbidity, and mortality. The actual etiology behind the development of MDD is not understood yet. Various genetic, physiological, biological and environmental factors have been predicted to be involved. As there is currently no sufficient laboratory test for the diagnosis of MDD, it is expected that this investigation can assist in better diagnosis and management of MDD. The present study aimed to evaluate glial cell line-derived neurotrophic factor (GDNF) in MDD patients compared to healthy controls (HCs). Materials and methods This case-control study was conducted with 167 participants including 85 MDD patients and 82 age- and sex-matched HCs. A qualified psychiatrist evaluated all the study participants according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5). The severity of depression was measured by the Hamilton depression rating scale (Ham-D) and the participants with Ham-D score ≥ 7 were considered as cases. Serum GDNF levels were determined by enzyme-linked immunosorbent assay (ELISA) kits (Boster Bio, Pleasanton, CA, USA). Results MDD patients and HCs were similar in terms of their socio-demographic profiles. Serum GDNF was found to have no significant alterations in MDD patients when compared to HCs (p > 0.05). Moreover, no significant positive or negative correlation was found between serum levels of GDNF and Ham-D scores in MDD patients. Conclusions It can be predicted from the above findings that there is no significant relation between serum GDNF levels and the pathophysiology of depression. This study should be treated as preliminary and further studies with a more homogeneous and larger study population are required to establish these findings.